Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes

Endocrine

Volumn 50, Issue 3, 2015, Pages 659-664

  Aso, Yoshimasa ^a   Jojima, T ^a   Iijima, T ^a   Suzuki, K ^a   Terasawa, T ^a   Fukushima, M ^b   Momobayashi, A ^b   Hara, K ^a   Takebayashi, K ^a   Kasai, K ^c   Inukai, T ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

^c Ishibashi General Hospital   (Japan)

Author keywords

Chemokines; Endothelial progenitor cells; Sitagliptin

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIMEPIRIDE; METFORMIN; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1ALPHA; CXCR4 PROTEIN, HUMAN; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADULT; AGED; ARTICLE; CD34+CXCR4+ CELL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; JAPAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; DIABETES MELLITUS, TYPE 2; MIDDLE AGED;

AGED; ANTIGENS, CD34; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CXCR4; SITAGLIPTIN PHOSPHATE;

EID: 84949089908     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0688-5     Document Type: Article

References (18)

1. T. Asahara, T. Murohara, A. Sullivan, M. Silver, R. van der Zee, T. Li, B. Witzenbichler, G. Schatteman, J.M. Isner, Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964–967 (1997)
2. T. Takahashi, C. Kalka, H. Masuda, D. Chen, M. Silver, M. Kearney, M. Magner, J.M. Isner, T. Asahara, Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5, 434–438 (1999)
3. O.M. Tepper, R.D. Galiano, J.M. Capla, C. Kalka, P.J. Gagne, G.R. Jacobowitz, J.P. Levine, G.C. Gurtner, Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106, 2781–2786 (2002)
4. G.P. Fadini, M. Miorin, M. Facco, S. Bonamico, I. Baesso, F. Grego, M. Menegolo, S.V. de Kreutzenberg, A. Tiengo, C. Agostini, A. Avogaro, Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J. Am. Coll. Cardiol. 45, 1449–1457 (2005)
5. S.K. Ghadge, S. Mühlstedt, C. Ozcelik, M. Bader, SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol. Ther. 129, 97–108 (2011)
6. A.M. Lambeir, C. Durinx, S. Scharpé, I. De Meester, Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209–294 (2003)
7. G.P. Fadini, E. Boscaro, M. Albiero, L. Menegazzo, V. Frison, S. de Kreutzenberg, C. Agostini, A. Tiengo, A. Avogaro, The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 33, 1607–1609 (2010)
8. + stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 110, 3213–3220 (2004)
9. G.P. Fadini, D. Losordo, S. Dimmeler, Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ. Res. 110, 624–637 (2012)
10. A. Antonelli, S.M. Ferrari, D. Giuggioli, E. Ferrannini, C. Ferri, P. Fallahi, Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev. 13, 272–280 (2014)
11. Y. Aso, N. Ozeki, T. Terasawa, R. Naruse, K. Hara, M. Suetsugu, K. Takebayashi, M. Shibazaki, K. Haruki, K. Morita, T. Inukai, Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl. Res. 159, 25–31 (2012)
12. C.G. Egan, R. Lavery, F. Caporali, C. Fondelli, F. Laghi-Pasini, F. Dotta, V. Sorrentino, Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 51, 1296–1305 (2008)
13. + stem/progenitor cells and the parameters of left ventricular function and remodeling in 1-year follow-up of patients with acute myocardial infarction. Mediat Inflamm. 2012, 56402 (2012)
14. + hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 91, 4523–4530 (1998)
15. R&D Systems, Inc., Datasheet. Quantikine. Human CXCL12/SDF-1α immunoassay. (R&D Systems, Inc., Minneapolis, 2014), pp. 1–10
16. M. Dettin, A. Pasquato, C. Scarinci, M. Zanchetta, A. De Rossi, C. Di Bello, Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1. J. Med. Chem. 47, 3058–3064 (2004)
17. T. Kusuyama, T. Omura, D. Nishiya, S. Enomoto, R. Matsumoto, K. Takeuchi, J. Yoshikawa, M. Yoshiyama, Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J. Pharmacol. Sci. 102, 96–102 (2006)
18. G.P. Fadini, A. Avogaro, Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis 229, 23–97 (2013)